Leslie et al. [147] identified TANs, which over-expressed the neutrophil receptor CXCR2, as key factors underlying the inferior efficacy of anti-PD-1 therapy in NASH-related HCC. The gene discussed is CXCR2; the disease is metabolic dysfunction-associated steatohepatitis.